Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine (Q34730892)

4 August 2017

1 reference

title

Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine (English)

1 reference

4 August 2017

Luisa Lina Villa

1

1 reference

4 August 2017

publication date

1 November 2007

1 reference

International Journal of Infectious Diseases

4 August 2017

published in

1 reference

4 August 2017

volume

11 Suppl 2

1 reference

4 August 2017

page(s)

S17-25

1 reference

Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

A population-based study of squamous cell vaginal cancer: HPV and cofactors

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Sexually transmitted infection as a cause of anal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

The male role in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Efficacy and other milestones for human papillomavirus vaccine introduction

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Vaccinating men for HPV: new strategy for preventing cervical cancer in women?

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960017-4

7 January 2021

10.1016/S1201-9712(07)60017-4

Identifiers

DOI

1 reference

4 August 2017

1 reference